News and Advisories
News/Advisories
March 7, 2024
CDC study reports "Early data from the New Vaccine Surveillance Network show nirsevimab is 90% effective in preventing infants from being hospitalized with RSV." Click here to learn more.
November 13, 2023
AstraZeneca Prioritizes US for RSV Drug Amid Surge in Cases
On Friday, November 10, 2023 AstraZeneca reported that in collaboration with Sanofi, the U.S. is to receive more doses of its RSV drug Beyfortus due to an increase in cases across the U.S. which is greater than the current supply. Click here to learn more.
November 10, 2023
On November 3, 2023 the AAP updated its Frequently Asked Question on nirsevimab (also known as Beyfortus). Please be sure to read the updated document. Click here to learn more.
October 6, 2023
CDC’s Morbidity and Mortality Weekly Report discusses seasonal administration of Pfizer’s RSV vaccine during pregnancy to prevent RSV in infants. Click here to learn more.
September 22, 2023
CDC recommends new vaccine during pregnancy to help protect babies against severe respiratory syncytial virus (RSV) illness after birth.
On September 22, 2023, the CDC recommended a new vaccine called Abrysvoä produced by Pfizer (bivalent RSVpreF vaccine) to help reduce severe illness in babies for the first six months of life. Results indicated a reduction in hospitalization for babies by 57 percent. The CDC recommended “seasonal administration of one dose of RSV vaccine” during weeks 32 through 36 of pregnancy. To learn more, click here.
September 5, 2023
Increased Respiratory Syncytial Virus (RSV) Activity in Parts of the Southeastern United States: New Prevention Tools Available to Protect Patients
The CDC reported on Tuesday, September 3 that there was increased RSV activity in parts of the southeast during the last few weeks potentially signaling an early start to the RSV season. Click here to read more.
August 3, 2023
The CDC announced a new tool to protect infants from severe RSV. According to their report, "CDC is recommending a new immunization starting this fall to protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory syncytial virus (RSV). Click here to read more.